Analysts Set Benitec Biopharma Limited (NASDAQ:BNTC) PT at $26.25

Shares of Benitec Biopharma Limited (NASDAQ:BNTC) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $26.25.

Several equities analysts have commented on the stock. HC Wainwright set a $32.00 target price on shares of Benitec Biopharma and gave the stock a “buy” rating in a research report on Monday, November 24th. Wall Street Zen raised Benitec Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a report on Wednesday, October 8th. Oppenheimer reissued an “outperform” rating and issued a $29.00 price target (down from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. Finally, JMP Securities set a $22.00 price objective on shares of Benitec Biopharma in a research report on Tuesday, November 4th.

Benitec Biopharma Trading Down 13.1%

Shares of Benitec Biopharma stock opened at $10.79 on Monday. The stock has a fifty day simple moving average of $13.99 and a 200 day simple moving average of $13.56. Benitec Biopharma has a 12-month low of $9.70 and a 12-month high of $17.15. The company has a market capitalization of $365.35 million, a P/E ratio of -8.92 and a beta of 0.20.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.13. On average, analysts predict that Benitec Biopharma will post -1.48 EPS for the current year.

Insider Activity

In other news, Director Suvretta Capital Management, L purchased 1,481,481 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was bought at an average price of $13.50 per share, for a total transaction of $19,999,993.50. Following the purchase, the director owned 9,538,175 shares of the company’s stock, valued at $128,765,362.50. The trade was a 18.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.80% of the stock is currently owned by insiders.

Institutional Trading of Benitec Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of BNTC. Infinitum Asset Management LLC boosted its holdings in Benitec Biopharma by 435.7% in the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock worth $14,636,000 after buying an additional 915,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Benitec Biopharma by 2.4% in the third quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company’s stock worth $13,919,000 after acquiring an additional 22,948 shares during the period. Geode Capital Management LLC grew its position in shares of Benitec Biopharma by 77.6% in the second quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company’s stock valued at $4,859,000 after purchasing an additional 181,391 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Benitec Biopharma by 40.5% in the third quarter. Ameriprise Financial Inc. now owns 154,414 shares of the biotechnology company’s stock worth $2,166,000 after buying an additional 44,489 shares in the last quarter. Finally, AWM Investment Company Inc. grew its stake in Benitec Biopharma by 35.2% during the first quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company’s stock valued at $1,795,000 after acquiring an additional 35,950 shares in the last quarter. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.